<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04953741</url>
  </required_header>
  <id_info>
    <org_study_id>KY20202053-F-1</org_study_id>
    <nct_id>NCT04953741</nct_id>
  </id_info>
  <brief_title>A Comparative Study on the Efficacy of Different Stepping-down Therapy for Childhood Asthma</brief_title>
  <official_title>A Comparative Study on the Efficacy of Different Stepping-down Therapy for Childhood Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a 24-week, randomized, parallel group comparative effectiveness study to&#xD;
      evaluate the risk of stepping down therapy for patients with well-controlled asthma treated&#xD;
      with combination Inhaled corticosteroids (ICS) and Leukotriene receptor antagonist（LTRA).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Asthma guidelines recommend stepping down therapy once asthma is controlled for at least 3&#xD;
      months. Leukotriene receptor antagonist（LTRA). For children with mild persistent asthma, ICS&#xD;
      twice a day combined with LTRA can be used for treatment, but there is no consensus on how to&#xD;
      reduce drugs in patients with asthma that is well controlled (reducing the dose of ICS or&#xD;
      stopping montelukast). We propose a 24-week, randomized, parallel group comparative&#xD;
      effectiveness study comparing three approaches in patients with asthma well-controlled for at&#xD;
      least three months on combination ICS and LTRA: Halve the dose of ICS firstly and then stop&#xD;
      ICS with montelukast only, stop montelukast firstly and then halve the dose of ICS, and halve&#xD;
      the dose of ICS firstly and then stop montelukast. Our goal is to compare the rate of&#xD;
      treatment failure and determine the optimal treatment strategy. Additional goals include&#xD;
      assessing risk factors for step-down failure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Asthma Control Test (ACT) score</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, 20 weeks and 24 weeks</time_frame>
    <description>Change in participant's Asthma Control Test (ACT) score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Experienced asthma exacerbation or used oral/intravenous corticosteroids as needed</measure>
    <time_frame>Baseline (Week 0) to Week 12</time_frame>
    <description>Participants Experienced asthma exacerbation or used oral/intravenous corticosteroids as needed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Experienced asthma exacerbation or used oral/intravenous corticosteroids as needed</measure>
    <time_frame>Baseline (Week 0) to Week 24</time_frame>
    <description>Participants Experienced asthma exacerbation or used oral/intravenous corticosteroids as needed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fractional exhaled Nitric Oxide, FeNO</measure>
    <time_frame>Baseline, 12 weeks and 24 weeks</time_frame>
    <description>Change in participant's Fractional exhaled Nitric Oxide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced expiratory volume in one second in predicted（FEV1%pred）</measure>
    <time_frame>Baseline, 12 weeks and 24 weeks</time_frame>
    <description>Change in participant's Forced expiratory volume in one second in predicted</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced vital capacity in predicted(FVC%pred)</measure>
    <time_frame>Baseline, 12 weeks and 24 weeks</time_frame>
    <description>Change in participant's Forced vital capacity in predicted</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal mid expiratory flow in predicted(MMEF%pred)</measure>
    <time_frame>Baseline, 12 weeks and 24 weeks</time_frame>
    <description>Change in participant's Maximal mid expiratory flow in predicted</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak expiratory flow (PEF)</measure>
    <time_frame>Baseline, 12 weeks and 24 weeks</time_frame>
    <description>Change in participant's Peak expiratory flow</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Asthma in Children</condition>
  <arm_group>
    <arm_group_label>Stop Fluticasone propionate Inhaled Aerosol Firstly</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day and continuation of montelukast once a day，and then stopped Fluticasone propionate Inhaled Aerosol and continuation of montelukast once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stop Montelukast Secondly</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day and continuation of montelukast once a day，and then stopped montelukast and continuation of Fluticasone propionate Inhaled Aerosol 125 ug once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stop Montelukast Firstly</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>stopped montelukast and continuation of Fluticasone propionate Inhaled Aerosol 125 ug twice daily, and then Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone propionate inhaled aerosol</intervention_name>
    <description>The study consists of two stages and include three groups. Three groups include: Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day and continuation of montelukast once a day，and then stopped Fluticasone propionate Inhaled Aerosol and continuation of montelukast once a day; Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day and continuation of montelukast once a day，and then stopped montelukast and continuation of Fluticasone propionate Inhaled Aerosol 125 ug once a day; Stopped montelukast and continuation of Fluticasone propionate Inhaled Aerosol 125 ug twice daily, and then Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day. The scheme of every group is divided into two stages. Only those whose asthma are well controlled at the end of the first phase will be allowed to proceed to the next phase.</description>
    <arm_group_label>Stop Fluticasone propionate Inhaled Aerosol Firstly</arm_group_label>
    <arm_group_label>Stop Montelukast Firstly</arm_group_label>
    <arm_group_label>Stop Montelukast Secondly</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age 4-14 years&#xD;
&#xD;
          -  patients had mild to moderate persistent asthma. Patients have treated with low-dose&#xD;
             inhaled corticosteroids (equivalent to Fluticasone propionate inhaled aerosol 250 ug/&#xD;
             day) combined with Leukotriene receptor antagonist (Montelulast) at least 6 months of&#xD;
             and had no symptoms of asthma for nearly 3 months under well asthma control(Asthma&#xD;
             Control Test (ACT) score more than or equal to 20).&#xD;
&#xD;
          -  patients did not suffer from other acute or chronic diseases that may affect their&#xD;
             growth and development&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with severe persistent asthma or mild persistent asthma failed to be well&#xD;
             controlled by low-dose ICS after starting treatment&#xD;
&#xD;
          -  suffer from other diseases: Congenital heart disease, chronic infectious disease,&#xD;
             protracted diarrhea, congenital airway disease, congenital vascular ring malformation,&#xD;
             congenital immune deficiency, tracheal foreign body, bronchial lymph node tuberculosis&#xD;
             and gastroesophageal reflux etc.&#xD;
&#xD;
          -  patients with poor compliance stop medication or fail to take medication on time.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xin Sun, doctor</last_name>
    <phone>+8613572536262</phone>
    <email>sunxin6@fmmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Pediatrics, Xijing Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xin Sun, doctor</last_name>
      <phone>+8613572536262</phone>
      <email>sunxin6@fmmu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Bernstein JA, Mansfield L. Step-up and step-down treatments for optimal asthma control in children and adolescents. J Asthma. 2019 Jul;56(7):758-770. doi: 10.1080/02770903.2018.1490752. Epub 2018 Sep 12. Review.</citation>
    <PMID>29972079</PMID>
  </results_reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>June 11, 2021</study_first_submitted>
  <study_first_submitted_qc>June 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2021</study_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Xhance</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

